Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Racial Differences in Vagal Control of Glucose Homeostasis
NCT03014323Phase 1Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of galantamine in insulin resistance (IR) (4 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Insulin Sensitivity at 4 weeks. Planned start Jan 2017; status: withdrawn.
02
Drugs
galantamine
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT03014323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014323.